Pittenger & Anderson Inc. Acquires 5,421 Shares of ResMed Inc. $RMD

Key Points

• Pittenger & Anderson increased its holding in ResMed by 5.5% in Q4, buying 5,421 shares to reach 103,373 shares worth about $24.9 million, making RMD its 29th-largest position.
• ResMed beat Q3 estimates with $2.86 EPS vs. $2.79 and revenue of $1.43B (up 10.8% YoY), and the board declared a $0.60 quarterly dividend (ex-dividend May 14, payable June 18).
• Insider selling has been notable—CEO Michael J. Farrell sold 4,991 shares and insiders sold 21,023 shares (~$5.23M) in the last 90 days—shares slipped about 4% and analysts remain mixed (consensus "Moderate Buy," average target ≈ $286; RBC $321).

Pittenger & Anderson Inc. boosted its holdings in shares of ResMed Inc. (NYSE:RMD - Free Report) by 5.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,373 shares of the medical equipment provider's stock after purchasing an additional 5,421 shares during the quarter. ResMed comprises approximately 1.0% of Pittenger & Anderson Inc.'s holdings, making the stock its 29th largest position. Pittenger & Anderson Inc. owned about 0.07% of ResMed worth $24,899,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in RMD. Terra Nova Asset Management LLC raised its holdings in ResMed by 0.6% in the 3rd quarter. Terra Nova Asset Management LLC now owns 7,805 shares of the medical equipment provider's stock valued at $2,136,000 after acquiring an additional 46 shares in the last quarter. NBT Bank N A NY raised its holdings in ResMed by 22.9% in the 3rd quarter. NBT Bank N A NY now owns 252 shares of the medical equipment provider's stock valued at $69,000 after acquiring an additional 47 shares in the last quarter. IMA Advisory Services Inc. raised its holdings in ResMed by 52.7% in the 3rd quarter. IMA Advisory Services Inc. now owns 139 shares of the medical equipment provider's stock valued at $38,000 after acquiring an additional 48 shares in the last quarter. Occidental Asset Management LLC raised its holdings in ResMed by 3.0% in the 4th quarter. Occidental Asset Management LLC now owns 1,699 shares of the medical equipment provider's stock valued at $409,000 after acquiring an additional 49 shares in the last quarter. Finally, New Wave Wealth Advisors LLC raised its holdings in ResMed by 2.8% in the 3rd quarter. New Wave Wealth Advisors LLC now owns 1,899 shares of the medical equipment provider's stock valued at $520,000 after acquiring an additional 52 shares in the last quarter. Institutional investors own 54.98% of the company's stock.

Insider Buying and Selling at ResMed

In other news, CEO Michael J. Farrell sold 4,991 shares of the firm's stock in a transaction on Monday, February 9th. The stock was sold at an average price of $273.78, for a total value of $1,366,435.98. Following the transaction, the chief executive officer directly owned 466,223 shares in the company, valued at $127,642,532.94. This trade represents a 1.06% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the firm's stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 21,023 shares of company stock worth $5,230,857 over the last 90 days. 0.65% of the stock is owned by corporate insiders.

ResMed Stock Down 4.0%

Shares of RMD opened at $205.17 on Friday. The firm has a market capitalization of $29.89 billion, a price-to-earnings ratio of 19.79, a PEG ratio of 1.35 and a beta of 0.85. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. The business's fifty day moving average price is $233.35 and its two-hundred day moving average price is $246.50. ResMed Inc. has a 52 week low of $198.64 and a 52 week high of $293.81.

ResMed (NYSE:RMD - Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $2.86 EPS for the quarter, beating analysts' consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The firm had revenue of $1.43 billion for the quarter, compared to analyst estimates of $1.42 billion. During the same period last year, the company earned $2.37 EPS. The business's quarterly revenue was up 10.8% compared to the same quarter last year. On average, analysts predict that ResMed Inc. will post 11.07 earnings per share for the current year.

ResMed Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Thursday, May 14th. ResMed's dividend payout ratio (DPR) is currently 23.74%.

Analyst Upgrades and Downgrades

RMD has been the subject of several recent research reports. Wall Street Zen cut ResMed from a "buy" rating to a "hold" rating in a report on Saturday, March 14th. Evercore set a $255.00 target price on ResMed and gave the stock an "outperform" rating in a report on Monday, April 13th. Royal Bank Of Canada increased their target price on ResMed from $314.00 to $321.00 and gave the stock an "outperform" rating in a report on Friday. Weiss Ratings cut ResMed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, March 19th. Finally, Citigroup decreased their price target on ResMed from $345.00 to $340.00 and set a "buy" rating on the stock in a research report on Thursday, April 9th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, ResMed has an average rating of "Moderate Buy" and a consensus price target of $286.18.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

ResMed Profile

ResMed NYSE: RMD is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed's product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.